Back to search results

Low Dose Whole Lung Radiation Therapy for COVID-19

This study is looking at whether a single, low dose of radiation therapy to the lungs can help patients with severe COVID-19 pneumonia. This treatment involves a type of X-ray that has been used in the past to reduce inflammation in the lungs. The study is for adults aged 18 and older who have been diagnosed with COVID-19 within 14 days, have pneumonia typical of COVID-19, and are on a ventilator in the ICU. Researchers want to see if this treatment can lower the death rate within 28 days after receiving the radiation. The study plans to enroll up to 24 patients.

Study design
This is an interventional study planning to enroll 24 participants. An interim review will happen after 16 patients to decide if the study should continue.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track the mortality rate of participants for up to 28 days after radiation delivery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04427566

Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise

Terminated
PHASE2Ages 18+InterventionalTreatment
Ohio State University
~2 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Radiation therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mortality Rate of Subjects Treated With Whole Lung Low-dose Radiation.
Measured over up to 1 month post radiation dose

Conditions

COVID-19

Explore related trials

COVID-19 Infection

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Arnab Chakravarti · PRINCIPAL_INVESTIGATOR · James Cancer Hospital, Department of Radiation Oncology

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Laboratory Diagnosis of COVID-19 based within 14 days of enrollment.
CT or radiographic findings typical of COVID-19 pneumonia within 5 days of enrollment
Receiving ICU-based mechanical ventilation
Life expectancy ≥ 24 hours, as judged by investigator
Hypoxemia defined as a Pa/FIO2 ratio \< 300 or SpO2/FiO2 \< 315
Signed informed consent by patient or his or her legal/authorized representative

Exclusion

Moribund with survival expected \< 24 hours, as judged by investigator and treating team
Expected survival \< 30 days, as judged by investigator and treating team, due to chronic illness present prior to COVID infection
Patient or legal representative not committed to full disease specific therapy, i.e. comfort care (DNRCCA is allowed)
Treatment with immune suppressing medications in the last 30 days (steroids for acute respiratory distress syndrome or septic shock allowed)
Presumed COVID-associated illness greater than 14-days
Inpatient admission greater than 14-days
Patient deemed unsafe for travel for radiation therapy
Chronic hypoxemia requiring supplemental oxygen at baseline
Documented active connective tissue disease (scleroderma) or idiopathic pulmonary fibrosis
History of prior radiation therapy resulting in ≥grade 2 radiation pneumonitis within 365 days of enrollment
Active or history of prior radiation to the thorax completed within 180 days of enrollment (skin or surface only skin treatments are acceptable)
Known active uncontrolled bacterial or fungal infections of the lung.
Active cytotoxic chemotherapy
Females who are pregnant or have a positive pregnancy test
Breast feeding
Note: concurrent administration of convalescent immune plasma therapy either on clinical trial or as a standard therapy not an exclusion criterion, but will be noted

What this trial measures

  • Mortality Rate of Subjects Treated With Whole Lung Low-dose Radiation.up to 1 month post radiation dose

    Number of subjects who expire from the date of radiation up to 1 month post radiation dose. The date will be collected if subject expires